WAM
NBIX icon

Wealthspire Advisors (Maryland)’s Neurocrine Biosciences NBIX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-412
Closed -$36K – 1443
2019
Q1 		$36K Buy
412
+370
+881% +$30.9K ﹤0.01% 1039
2018
Q4 		$3K Sell
42
-27
-39% -$2.59K ﹤0.01% 1966
2018
Q3 		$8K Hold
69
– – ﹤0.01% 1615
2018
Q2 		$7K Buy
69
+18
+35% +$1.61K ﹤0.01% 1671
2018
Q1 		$4K Buy
51
+3
+6% +$253 ﹤0.01% 1919
2017
Q4 		$4K Buy
48
+20
+71% +$1.36K ﹤0.01% 1911
2017
Q3 		$2K Buy
28
+5
+22% +$264 ﹤0.01% 1997
2017
Q2 		$1K Buy
23
+14
+156% +$679 ﹤0.01% 2100
2017
Q1 		$0 Buy
+9
New +$386 ﹤0.01% 1983
2016
Q4 		– Sell
-3
Closed – – 1813
2016
Q3 		$0 Buy
+3
New +$149 ﹤0.01% 1784

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s NBIX Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 412 shares — an estimated $36K sold.

Wealthspire Advisors (Maryland) first reported a position in NBIX in Q3 2016 and held it in 10 quarters. The position peaked at $36K in Q1 2019. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 412 Neurocrine Biosciences shares in Q2 2019, an estimated $36K.
  • Wealthspire Advisors (Maryland) first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 10 quarters.
  • Wealthspire Advisors (Maryland)'s Neurocrine Biosciences position peaked at $36K in Q1 2019.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.